WO2013044176A3 - Methods and compositions for the treatment of ischemic stroke - Google Patents

Methods and compositions for the treatment of ischemic stroke Download PDF

Info

Publication number
WO2013044176A3
WO2013044176A3 PCT/US2012/056760 US2012056760W WO2013044176A3 WO 2013044176 A3 WO2013044176 A3 WO 2013044176A3 US 2012056760 W US2012056760 W US 2012056760W WO 2013044176 A3 WO2013044176 A3 WO 2013044176A3
Authority
WO
WIPO (PCT)
Prior art keywords
dha
treatment
methods
compositions
ischemic stroke
Prior art date
Application number
PCT/US2012/056760
Other languages
French (fr)
Other versions
WO2013044176A2 (en
Inventor
Nicolas G. Bazan
Nicos A. Petasis
Charles N. Serhan
Ludmila Belayev
Original Assignee
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southern California filed Critical University Of Southern California
Publication of WO2013044176A2 publication Critical patent/WO2013044176A2/en
Publication of WO2013044176A3 publication Critical patent/WO2013044176A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention provides compounds, methods and compositions for the treatment of ischemic stroke, comprising the timely administration of doeosahexaenoic acid (DHA), a combination of DHA and aspirin, or a neuroprotective 10,17-dihydroxyl derivative of DHA. In particular, the invention provides treatment methods within up to 6h following focal ischemia, by administering a composition comprising DHA, a combination of DHA and aspirin, or a neuroprotective 10,17-dihydroxyl derivative of DHA. The invention also provides a non-invasive method for monitoring the progression of the treatment.
PCT/US2012/056760 2011-09-23 2012-09-21 Methods and compositions for the treatment of ischemic stroke WO2013044176A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538504P 2011-09-23 2011-09-23
US61/538,504 2011-09-23

Publications (2)

Publication Number Publication Date
WO2013044176A2 WO2013044176A2 (en) 2013-03-28
WO2013044176A3 true WO2013044176A3 (en) 2013-07-11

Family

ID=47046843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/056760 WO2013044176A2 (en) 2011-09-23 2012-09-21 Methods and compositions for the treatment of ischemic stroke

Country Status (1)

Country Link
WO (1) WO2013044176A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633324B2 (en) * 2015-02-09 2020-04-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060778A2 (en) * 2000-02-16 2001-08-23 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
WO2005013908A2 (en) * 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration
WO2007041440A2 (en) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007059431A1 (en) * 2005-11-14 2007-05-24 The Trustees Of Columbia University In The City Of New York Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060778A2 (en) * 2000-02-16 2001-08-23 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
WO2005013908A2 (en) * 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration
WO2007041440A2 (en) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007059431A1 (en) * 2005-11-14 2007-05-24 The Trustees Of Columbia University In The City Of New York Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHARLESN SERHAN ET AL: "Novel Proresolving Aspirin-Triggered DHA Pathway", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 18, no. 8, 20 June 2011 (2011-06-20), pages 976 - 987, XP028272023, ISSN: 1074-5521, [retrieved on 20110629], DOI: 10.1016/J.CHEMBIOL.2011.06.008 *
LUDMILA BELAYEV ET AL: "Docosahexaenoic Acid Therapy of Experimental Ischemic Stroke", TRANSLATIONAL STROKE RESEARCH, vol. 2, no. 1, 4 November 2010 (2010-11-04), pages 33 - 41, XP055045848, ISSN: 1868-4483, DOI: 10.1007/s12975-010-0046-0 *
MARCHESELLI V L ET AL: "Novel Docosanoids Inhibit Brain Ischemia-Reperfusion-mediated Leukocyte Infiltration and Pro-inflammatory Gene Expression", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 278, no. 44, 31 October 2003 (2003-10-31), pages 43807 - 43817, XP002267882, ISSN: 0021-9258, DOI: 10.1074/JBC.M305841200 *
N. G. BAZAN: "Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease", THE JOURNAL OF LIPID RESEARCH, vol. 50, no. Supplement, 1 April 2009 (2009-04-01), pages S400 - S405, XP055045874, ISSN: 0022-2275, DOI: 10.1194/jlr.R800068-JLR200 *
SERHAN C N ET AL: "Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis", PROSTAGLANDINS AND OTHER LIPID MEDIATORS, ELSEVIER, US, vol. 73, no. 3-4, 1 April 2004 (2004-04-01), pages 155 - 172, XP004515307, ISSN: 1098-8823, DOI: 10.1016/J.PROSTAGLANDINS.2004.03.005 *

Also Published As

Publication number Publication date
WO2013044176A2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
GT201200250A (en) ARILTRIAZOLONAS LINKED TO BISARILO AND ITS USE
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
CL2014003475A1 (en) C-crystalline form of obetolic acid; process of preparation of the form 1 of obetolic acid from the crystalline form c; pharmaceutical composition comprising a crystalline form of obetolic acid, useful for the treatment or prevention of cholestatic liver disease, alcoholic liver disease and cardiovascular diseases such as atherosclerosis, among others.
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
MX349950B (en) Carrier-linked treprostinil prodrugs.
CL2013003372A1 (en) Compounds derived from spiro- [1,3] -oxacins and spiro- [1,4] -oxacepins, inhibitors of bace1 and / or bace2; pharmaceutical composition; procedure to prepare them; and its use in the treatment and / or prophylaxis of Alzheimer's disease and diabetes.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
BR112015000229A2 (en) stable aqueous formulations of etanercept
WO2015066426A3 (en) Angiopoietin-based interventions for treating cerebral malaria
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
WO2014153009A3 (en) Thiosaccharide mucolytic agents
MX344473B (en) Semisolid aqueous pharmaceutical composition containing tapentadol.
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
WO2014179567A3 (en) Methods and compositions for treating beta-thalassemia and sickle cell disease
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12775367

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12775367

Country of ref document: EP

Kind code of ref document: A2